Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | GCGR | P47871 | 8/20 | 0.44 |
| ▸ | GIPR | P48546 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | EIF4E | P06730 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585721 | 0.91 | KMT2A (0.46) | MEN1KMT2ANPC1KDM4ERAB9A | |
| SCHEMBL5585892 | 0.86 | NPC1 (0.49) | MEN1KMT2ANPC1KDM4ERAB9A | |
| SCHEMBL5585545 | 0.85 | HRH3 (0.43) | MEN1KMT2ANPC1KDM4ERAB9A | |
| SCHEMBL5585797 | 0.84 | KDM4E (0.47) | MEN1KMT2ANPC1KDM4ERAB9A | |
| SCHEMBL5585686 | 0.81 | KMT2A (0.47) | MEN1KMT2ANPC1KDM4ERAB9A | |
| SCHEMBL5585293 | 0.76 | RXRA (0.50) | MEN1KMT2ANPC1KDM4ERAB9A | |
| SCHEMBL5585418 | 0.76 | CSNK2A1 (0.62) | MEN1KMT2ANPC1KDM4ERAB9A | |
| SCHEMBL6154899 | 0.74 | GCGR (0.57) | MEN1KMT2ANPC1KDM4ERAB9A | |
| SCHEMBL5585511 | 0.73 | MAOB (0.41) | MEN1KMT2AGCGRGIPRALKBH1 | |
| SCHEMBL4956655 | 0.73 | GCGR (0.56) | MEN1KMT2ANPC1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | MEN1 3299/4885KMT2A 2589/4885NPC1 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.